Old TB vaccine tested for brain benefits in seniors

NCT ID NCT04507126

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study gave the BCG vaccine (used for tuberculosis) to 20 healthy older adults aged 55-80. Researchers measured changes in immune markers and Alzheimer's-related proteins in blood and spinal fluid over 90 days. The goal was to see if this common vaccine might influence brain inflammation and related biomarkers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BCG vaccine

What this could lead to

If successful, this could point toward a way to use an existing vaccine to reduce brain inflammation and potentially lower Alzheimer's risk.

What could go wrong

This is a very small pilot study with only 20 healthy older adults. It only looks at biomarker changes, not whether BCG actually prevents or treats any disease. Results may not apply to the general population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Clinical Translational Research Unit

    Charlestown, Massachusetts, 02124, United States